Top

Published in:

Open Access 01-12-2007 | Review

The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention

Author: John P Alao

Published in: Molecular Cancer | Issue 1/2007

Abstract

Cyclin D1 is an important regulator of cell cycle progression and can function as a transcriptionl co-regulator. The overexpression of cyclin D1 has been linked to the development and progression of cancer. Deregulated cyclin D1 degradation appears to be responsible for the increased levels of cyclin D1 in several cancers. Recent findings have identified novel mechanisms involved in the regulation of cyclin D1 stability. A number of therapeutic agents have been shown to induce cyclin D1 degradation. The therapeutic ablation of cyclin D1 may be useful for the prevention and treatment of cancer. In this review, current knowledge on the regulation of cyclin D1 degradation is discussed. Novel insights into cyclin D1 degradation are also discussed in the context of ablative therapy. A number of unresolved questions regarding the regulation of cellular cyclin D1 levels are also addressed.

Available only for authorised users

Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 1993, 7 (3): 331-342.PubMed

Lundberg AS, Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol. 1998, 18 (2): 753-761.PubMedCentralPubMed

Weinberg RA: The retinoblastoma protein and cell cycle control. Cell. 1995, 81 (3): 323-330. 10.1016/0092-8674(95)90385-2PubMed

Coqueret O: Linking cyclins to transcriptional control. Gene. 2002, 299 (1-2): 35-55. 10.1016/S0378-1119(02)01055-7PubMed

Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 1998, 12 (22): 3499-3511.PubMedCentralPubMed

Diehl JA, Zindy F, Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997, 11 (8): 957-972.PubMed

Yu ZK, Gervais JL, Zhang H: Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins. Proc Natl Acad Sci U S A. 1998, 95 (19): 11324-11329. 10.1073/pnas.95.19.11324PubMedCentralPubMed

Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, Rustgi A, Fuchs SY, Diehl JA: Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex. Mol Cell. 2006, 24 (3): 355-366. 10.1016/j.molcel.2006.09.007PubMedCentralPubMed

Okabe H, Lee SH, Phuchareon J, Albertson DG, McCormick F, Tetsu O: A Critical Role for FBXW8 and MAPK in Cyclin D1 Degradation and Cancer Cell Proliferation. PLoS ONE. 2006, 1: e128- 10.1371/journal.pone.0000128PubMedCentralPubMed

10.

Hall M, Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 1996, 68: 67-108.PubMed

11.

Vermeulen K, Van Bockstaele DR, Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003, 36 (3): 131-149. 10.1046/j.1365-2184.2003.00266.xPubMed

12.

Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D: Cyclin D1 and prognosis in human breast cancer. Int J Cancer. 1996, 69 (2): 92-99. 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.0.CO;2-QPubMed

13.

Knudsen KE, Diehl JA, Haiman CA, Knudsen ES: Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006, 25 (11): 1620-1628. 10.1038/sj.onc.1209371PubMed

14.

Motokura T, Arnold A: Cyclin D and oncogenesis. Curr Opin Genet Dev. 1993, 3 (1): 5-10. 10.1016/S0959-437X(05)80334-XPubMed

15.

Musgrove EA: Cyclins: roles in mitogenic signaling and oncogenic transformation. Growth Factors. 2006, 24 (1): 13-19.PubMed

16.

Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell. 1995, 82 (4): 621-630. 10.1016/0092-8674(95)90034-9PubMed

17.

Sutherland RL, Musgrove EA: Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res. 2002, 4 (1): 14-17. 10.1186/bcr411PubMedCentralPubMed

18.

Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med. 1995, 1 (12): 1257-1260. 10.1038/nm1295-1257PubMed

19.

Yamamoto M, Tamakawa S, Yoshie M, Yaginuma Y, Ogawa K: Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. Mol Carcinog. 2006, 45 (12): 901-913. 10.1002/mc.20204PubMed

20.

Hodges LC, Cook JD, Lobenhofer EK, Li L, Bennett L, Bushel PR, Aldaz CM, Afshari CA, Walker CL: Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res. 2003, 1 (4): 300-311.PubMed

21.

Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA, Sutherland RL: Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res. 2002, 62 (23): 6916-6923.PubMed

22.

Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, Robertson JF: Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res. 1999, 5 (8): 2069-2076.PubMed

23.

Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 1994, 54 (7): 1812-1817.PubMed

24.

Russell A, Thompson MA, Hendley J, Trute L, Armes J, Germain D: Cyclin D1 and D3 associate with the SCF complex and are coordinately elevated in breast cancer. Oncogene. 1999, 18 (11): 1983-1991. 10.1038/sj.onc.1202511PubMed

25.

Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DM: Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res. 2004, 10 (23): 8094-8104. 10.1158/1078-0432.CCR-04-1023PubMed

26.

Alao JP, Stavropoulou AV, Lam EW, Coombes RC, Vigushin DM: Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer. 2006, 5: 8- 10.1186/1476-4598-5-8PubMedCentralPubMed

27.

Feng Q, Sekula D, Muller R, Freemantle SJ, Dmitrovsky E: Uncovering residues that regulate cyclin D1 proteasomal degradation. Oncogene. 2007,

28.

Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, Shapiro CL, Chen CS: Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol. 2005, 67 (4): 1342-1348. 10.1124/mol.104.007732PubMed

29.

Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E: Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci U S A. 1997, 94 (22): 12070-12074. 10.1073/pnas.94.22.12070PubMedCentralPubMed

30.

Spinella MJ, Freemantle SJ, Sekula D, Chang JH, Christie AJ, Dmitrovsky E: Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation. J Biol Chem. 1999, 274 (31): 22013-22018. 10.1074/jbc.274.31.22013PubMed

31.

Dragnev KH, Petty WJ, Dmitrovsky E: Retinoid targets in cancer therapy and chemoprevention. Cancer Biol Ther. 2003, 2 (4 Suppl 1): S150-6.PubMed

32.

Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001, 411: 1017-1021. 10.1038/35082500PubMed

33.

Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G: Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993, 7 (5): 812-821.PubMed

34.

Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA: Physical interaction of the retinoblastoma protein with human D cyclins. Cell. 1993, 73 (3): 499-511. 10.1016/0092-8674(93)90137-FPubMed

35.

Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM: Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell. 1993, 73 (3): 487-497. 10.1016/0092-8674(93)90136-EPubMed

36.

Fu M, Wang C, Li Z, Sakamaki T, Pestell RG: Minireview: Cyclin D1: normal and abnormal functions. Endocrinology. 2004, 145 (12): 5439-5447. 10.1210/en.2004-0959PubMed

37.

Hatakeyama M, Brill JA, Fink GR, Weinberg RA: Collaboration of G1 cyclins in the functional inactivation of the retinoblastoma protein. Genes Dev. 1994, 8 (15): 1759-1771.PubMed

38.

Fukami-Kobayashi J, Mitsui Y: Cyclin D1 inhibits cell proliferation through binding to PCNA and cdk2. Exp Cell Res. 1999, 246 (2): 338-347. 10.1006/excr.1998.4306PubMed

39.

Pagano M, Theodoras AM, Tam SW, Draetta GF: Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev. 1994, 8 (14): 1627-1639.PubMed

40.

Alt JR, Cleveland JL, Hannink M, Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 2000, 14 (24): 3102-3114. 10.1101/gad.854900PubMedCentralPubMed

41.

Cross DA, Alessi DR, Vandenheede JR, McDowell HE, Hundal HS, Cohen P: The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf. Biochem J. 1994, 303 ( Pt 1): 21-26.

42.

Saito Y, Vandenheede JR, Cohen P: The mechanism by which epidermal growth factor inhibits glycogen synthase kinase 3 in A431 cells. Biochem J. 1994, 303 ( Pt 1): 27-31.

43.

Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, Hitomi M, Stacey DW: Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene. 2005, 24 (16): 2599-2612. 10.1038/sj.onc.1208326PubMed

44.

Yang K, Guo Y, Stacey WC, Harwalkar J, Fretthold J, Hitomi M, Stacey DW: Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels. BMC Cell Biol. 2006, 7: 33- 10.1186/1471-2121-7-33PubMedCentralPubMed

45.

Alao JP, Gamble SC, Stavropoulou AV, Pomeranz KM, Lam EW, Coombes RC, Vigushin DM: The cyclin D1 proto-oncogene is sequestered in the cytoplasm of mammalian cancer cell lines. Mol Cancer. 2006, 5: 7- 10.1186/1476-4598-5-7PubMedCentralPubMed

46.

Germain D, Russell A, Thompson A, Hendley J: Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. J Biol Chem. 2000, 275 (16): 12074-12079. 10.1074/jbc.275.16.12074PubMed

47.

Zou Y, Ewton DZ, Deng X, Mercer SE, Friedman E: Mirk/dyrk1B kinase destabilizes cyclin D1 by phosphorylation at threonine 288. J Biol Chem. 2004, 279 (26): 27790-27798. 10.1074/jbc.M403042200PubMed

48.

Agami R, Bernards R: Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 2000, 102 (1): 55-66. 10.1016/S0092-8674(00)00010-6PubMed

49.

Casanovas O, Miro F, Estanyol JM, Itarte E, Agell N, Bachs O: Osmotic stress regulates the stability of cyclin D1 in a p38SAPK2-dependent manner. J Biol Chem. 2000, 275 (45): 35091-35097. 10.1074/jbc.M006324200PubMed

50.

Mikhailov A, Shinohara M, Rieder CL: Topoisomerase II and histone deacetylase inhibitors delay the G2/M transition by triggering the p38 MAPK checkpoint pathway. J Cell Biol. 2004, 166 (4): 517-526. 10.1083/jcb.200405167PubMedCentralPubMed

51.

Dmitrieva NI, Burg MB: Hypertonic stress response. Mutat Res. 2005, 569 (1-2): 65-74.PubMed

52.

Dmitrieva NI, Burg MB, Ferraris JD: DNA damage and osmotic regulation in the kidney. Am J Physiol Renal Physiol. 2005, 289 (1): F2-7. 10.1152/ajprenal.00041.2005PubMed

53.

Stacey DW: Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol. 2003, 15 (2): 158-163. 10.1016/S0955-0674(03)00008-5PubMed

54.

Yang K, Hitomi M, Stacey DW: Variations in cyclin D1 levels through the cell cycle determine the proliferative fate of a cell. Cell Div. 2006, 1: 32- 10.1186/1747-1028-1-32PubMedCentralPubMed

55.

Luo H, Zhang J, Dastvan F, Yanagawa B, Reidy MA, Zhang HM, Yang D, Wilson JE, McManus BM: Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J Virol. 2003, 77 (1): 1-9. 10.1128/JVI.77.1.1-9.2003PubMedCentralPubMed

56.

Newman RM, Mobascher A, Mangold U, Koike C, Diah S, Schmidt M, Finley D, Zetter BR: Antizyme targets cyclin D1 for degradation. A novel mechanism for cell growth repression. J Biol Chem. 2004, 279 (40): 41504-41511. 10.1074/jbc.M407349200PubMed

57.

Fong LY, Feith DJ, Pegg AE: Antizyme overexpression in transgenic mice reduces cell proliferation, increases apoptosis, and reduces N-nitrosomethylbenzylamine-induced forestomach carcinogenesis. Cancer Res. 2003, 63 (14): 3945-3954.PubMed

58.

Iwata S, Sato Y, Asada M, Takagi M, Tsujimoto A, Inaba T, Yamada T, Sakamoto S, Yata J, Shimogori T, Igarashi K, Mizutani S: Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation. Oncogene. 1999, 18 (1): 165-172. 10.1038/sj.onc.1202275PubMed

59.

Tsuji T, Usui S, Aida T, Tachikawa T, Hu GF, Sasaki A, Matsumura T, Todd R, Wong DT: Induction of epithelial differentiation and DNA demethylation in hamster malignant oral keratinocyte by ornithine decarboxylase antizyme. Oncogene. 2001, 20 (1): 24-33. 10.1038/sj.onc.1204051PubMed

60.

Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J: Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995, 11 (5): 1005-1011.PubMed

61.

Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV, Arnold A: Cyclin D1 (PRAD1) alternative transcript b: full-length cDNA cloning and expression in breast cancers. Cancer Lett. 1997, 113 (1-2): 123-130. 10.1016/S0304-3835(97)04605-3PubMed

62.

Lu F, Gladden AB, Diehl JA: An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003, 63 (21): 7056-7061.PubMed

63.

Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES: Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 2003, 278 (32): 30339-30347. 10.1074/jbc.M303969200PubMed

64.

Burd CJ, Petre CE, Morey LM, Wang Y, Revelo MP, Haiman CA, Lu S, Fenoglio-Preiser CM, Li J, Knudsen ES, Wong J, Knudsen KE: Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A. 2006, 103 (7): 2190-2195. 10.1073/pnas.0506281103PubMedCentralPubMed

65.

Knudsen KE: The cyclin D1b splice variant: an old oncogene learns new tricks. Cell Div. 2006, 1: 15- 10.1186/1747-1028-1-15PubMedCentralPubMed

66.

Deshaies RJ: SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol. 1999, 15: 435-467. 10.1146/annurev.cellbio.15.1.435PubMed

67.

Hermand D: F-box proteins: more than baits for the SCF?. Cell Div. 2006, 1: 30- 10.1186/1747-1028-1-30PubMedCentralPubMed

68.

Petroski MD, Deshaies RJ: Mechanism of lysine 48-linked ubiquitin-chain synthesis by the cullin-RING ubiquitin-ligase complex SCF-Cdc34. Cell. 2005, 123 (6): 1107-1120. 10.1016/j.cell.2005.09.033PubMed

69.

Petroski MD, Deshaies RJ: In vitro reconstitution of SCF substrate ubiquitination with purified proteins. Methods Enzymol. 2005, 398: 143-158.PubMed

70.

Seol JH, Feldman RM, Zachariae W, Shevchenko A, Correll CC, Lyapina S, Chi Y, Galova M, Claypool J, Sandmeyer S, Nasmyth K, Deshaies RJ, Shevchenko A, Deshaies RJ: Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. Genes Dev. 1999, 13 (12): 1614-1626.PubMedCentralPubMed

71.

Abdolzade-Bavil A, Hayes S, Goretzki L, Kroger M, Anders J, Hendriks R: Convenient and versatile subcellular extraction procedure, that facilitates classical protein expression profiling and functional protein analysis. Proteomics. 2004, 4 (5): 1397-1405. 10.1002/pmic.200300710PubMed

72.

Chung JH, Eng C: Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res. 2005, 65 (18): 8096-8100. 10.1158/0008-5472.CAN-05-1888PubMed

73.

Krieger S, Gauduchon J, Roussel M, Troussard X, Sola B: Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma. BMC Cancer. 2006, 6: 238- 10.1186/1471-2407-6-238PubMedCentralPubMed

74.

Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM: PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol. 2003, 23 (17): 6139-6149. 10.1128/MCB.23.17.6139-6149.2003PubMedCentralPubMed

75.

Sumrejkanchanakij P, Tamamori-Adachi M, Matsunaga Y, Eto K, Ikeda MA: Role of cyclin D1 cytoplasmic sequestration in the survival of postmitotic neurons. Oncogene. 2003, 22 (54): 8723-8730. 10.1038/sj.onc.1206870PubMed

76.

Tamamori-Adachi M, Ito H, Sumrejkanchanakij P, Adachi S, Hiroe M, Shimizu M, Kawauchi J, Sunamori M, Marumo F, Kitajima S, Ikeda MA: Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation. Circ Res. 2003, 92 (1): e12-9. 10.1161/01.RES.0000049105.15329.1CPubMed

77.

Alt JR, Gladden AB, Diehl JA: p21(Cip1) Promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem. 2002, 277 (10): 8517-8523. 10.1074/jbc.M108867200PubMed

78.

Smirnova IV, Bittel DC, Ravindra R, Jiang H, Andrews GK: Zinc and cadmium can promote rapid nuclear translocation of metal response element-binding transcription factor-1. J Biol Chem. 2000, 275 (13): 9377-9384. 10.1074/jbc.275.13.9377PubMed

79.

Dragnev KH, Feng Q, Ma Y, Shah SJ, Black C, Memoli V, Nugent W, Rigas JR, Kitareewan S, Freemantle S, Dmitrovsky E: Uncovering novel targets for cancer chemoprevention. Recent Results Cancer Res. 2007, 174: 235-243.PubMed

80.

Huang JW, Shiau CW, Yang J, Wang DS, Chiu HC, Chen CY, Chen CS: Development of small-molecule cyclin D1-ablative agents. J Med Chem. 2006, 49 (15): 4684-4689. 10.1021/jm060057hPubMed

81.

Blomhoff R, Blomhoff HK: Overview of retinoid metabolism and function. J Neurobiol. 2006, 66 (7): 606-630. 10.1002/neu.20242PubMed

82.

Lefebvre P, Martin PJ, Flajollet S, Dedieu S, Billaut X, Lefebvre B: Transcriptional activities of retinoic acid receptors. Vitam Horm. 2005, 70: 199-264. 10.1016/S0083-6729(05)70007-8PubMed

83.

Boyle JO, Langenfeld J, Lonardo F, Sekula D, Reczek P, Rusch V, Dawson MI, Dmitrovsky E: Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized, and transformed human bronchial epithelial cells. J Natl Cancer Inst. 1999, 91 (4): 373-379. 10.1093/jnci/91.4.373PubMed

84.

Mori J, Takahashi-Yanaga F, Miwa Y, Watanabe Y, Hirata M, Morimoto S, Shirasuna K, Sasaguri T: Differentiation-inducing factor-1 induces cyclin D1 degradation through the phosphorylation of Thr286 in squamous cell carcinoma. Exp Cell Res. 2005, 310 (2): 426-433. 10.1016/j.yexcr.2005.07.024PubMed

85.

Takahashi-Yanaga F, Mori J, Matsuzaki E, Watanabe Y, Hirata M, Miwa Y, Morimoto S, Sasaguri T: Involvement of GSK-3beta and DYRK1B in differentiation-inducing factor-3-induced phosphorylation of cyclin D1 in HeLa cells. J Biol Chem. 2006, 281 (50): 38489-38497. 10.1074/jbc.M605205200PubMed

86.

Takahashi-Yanaga F, Taba Y, Miwa Y, Kubohara Y, Watanabe Y, Hirata M, Morimoto S, Sasaguri T: Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3beta and degrades cyclin D1 in mammalian cells. J Biol Chem. 2003, 278 (11): 9663-9670. 10.1074/jbc.M205768200PubMed

87.

Morris HR, Masento MS, Taylor GW, Jermyn KA, Kay RR: Structure elucidation of two differentiation inducing factors (DIF-2 and DIF-3) from the cellular slime mould Dictyostelium discoideum. Biochem J. 1988, 249 (3): 903-906.PubMedCentralPubMed

88.

Morris HR, Taylor GW, Masento MS, Jermyn KA, Kay RR: Chemical structure of the morphogen differentiation inducing factor from Dictyostelium discoideum. Nature. 1987, 328 (6133): 811-814. 10.1038/328811a0PubMed

89.

Di Monte D, Jewell SA, Ekstrom G, Sandy MS, Smith MT: 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridine (MPP+) cause rapid ATP depletion in isolated hepatocytes. Biochem Biophys Res Commun. 1986, 137 (1): 310-315. 10.1016/0006-291X(86)91211-8PubMed

90.

Miyako K, Kai Y, Irie T, Takeshige K, Kang D: The content of intracellular mitochondrial DNA is decreased by 1-methyl-4-phenylpyridinium ion (MPP+). J Biol Chem. 1997, 272 (15): 9605-9608. 10.1074/jbc.272.15.9605PubMed

91.

Soldner F, Weller M, Haid S, Beinroth S, Miller SW, Wullner U, Davis RE, Dichgans J, Klockgether T, Schulz JB: MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). Exp Cell Res. 1999, 250 (1): 75-85. 10.1006/excr.1999.4504PubMed

92.

Bloem BR, Irwin I, Buruma OJ, Haan J, Roos RA, Tetrud JW, Langston JW: The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease. J Neurol Sci. 1990, 97 (2-3): 273-293. 10.1016/0022-510X(90)90225-CPubMed

93.

Langston JW, Irwin I: MPTP: current concepts and controversies. Clin Neuropharmacol. 1986, 9 (6): 485-507. 10.1097/00002826-198612000-00001PubMed

94.

Bai J, Nakamura H, Ueda S, Kwon YW, Tanaka T, Ban S, Yodoi J: Proteasome-dependent degradation of cyclin D1 in 1-methyl-4-phenylpyridinium ion (MPP+)-induced cell cycle arrest. J Biol Chem. 2004, 279 (37): 38710-38714. 10.1074/jbc.M403329200PubMed

95.

Sonoda H, Omi K, Hojo K, Nishida K, Omura S, Sugita K: Suppression of oncogenic transformation by hypothemycin associated with accelerated cyclin D1 degradation through ubiquitin-proteasome pathway. Life Sci. 1999, 65 (4): 381-394. 10.1016/S0024-3205(99)00259-3PubMed

96.

Wakita K, Minami M, Venkateswarlu A, Sharma VM, Ramesh M, Akahane K: Antitumor bicyclic hexapeptide RA-VII modulates cyclin D1 protein level. Anticancer Drugs. 2001, 12 (5): 433-439. 10.1097/00001813-200106000-00004

97.

Chang JY, Han FS, Liu SY, Wang ZQ, Lee KH, Cheng YC: Effect of 4 beta-arylamino derivatives of 4'-O-demethylepipodophyllotoxin on human DNA topoisomerase II, tubulin polymerization, KB cells, and their resistant variants. Cancer Res. 1991, 51 (7): 1755-1759.PubMed

98.

Huang TS, Lee CC, Chao Y, Shu CH, Chen LT, Chen LL, Chen MH, Yuan CC, Whang-Peng J: A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharm Res. 1999, 16 (7): 997-1002. 10.1023/A:1018971313256PubMed

99.

Lin S, Huang HC, Chen LL, Lee CC, Huang TS: GL331 induces down-regulation of cyclin D1 expression via enhanced proteolysis and repressed transcription. Mol Pharmacol. 2001, 60 (4): 768-775.PubMed

100.

Baur JA, Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006, 5 (6): 493-506. 10.1038/nrd2060PubMed

101.

Fulda S, Debatin KM: Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini-review. Cancer Detect Prev. 2006, 30 (3): 217-223. 10.1016/j.cdp.2006.03.007PubMed

102.

Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997, 275 (5297): 218-220. 10.1126/science.275.5297.218PubMed

103.

Joe AK, Liu H, Suzui M, Vural ME, Xiao D, Weinstein IB: Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res. 2002, 8 (3): 893-903.PubMed

104.

Ragione FD, Cucciolla V, Borriello A, Pietra VD, Racioppi L, Soldati G, Manna C, Galletti P, Zappia V: Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun. 1998, 250 (1): 53-58. 10.1006/bbrc.1998.9263PubMed

105.

Sharma RA, Gescher AJ, Steward WP: Curcumin: the story so far. Eur J Cancer. 2005, 41 (13): 1955-1968. 10.1016/j.ejca.2005.05.009PubMed

106.

Thangapazham RL, Sharma A, Maheshwari RK: Multiple molecular targets in cancer chemoprevention by curcumin. Aaps J. 2006, 8 (3): E443-9. 10.1208/aapsj080352PubMedCentralPubMed

107.

Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB: Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene. 2002, 21 (57): 8852-8861. 10.1038/sj.onc.1206048PubMed

108.

Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J: Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980, 77 (7): 3957-3961. 10.1073/pnas.77.7.3957PubMedCentralPubMed

109.

Keyomarsi K, Sandoval L, Band V, Pardee AB: Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991, 51 (13): 3602-3609.PubMed

110.

Poon RY, Toyoshima H, Hunter T: Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol Biol Cell. 1995, 6 (9): 1197-1213.PubMedCentralPubMed

111.

Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, Takano E, Maki M, Henkart PA, Trepel JB: Regulation of cyclin D1 by calpain protease. J Biol Chem. 1997, 272 (45): 28479-28484. 10.1074/jbc.272.45.28479PubMed

112.

Collier HO: New light on how aspirin works. Nature. 1969, 223 (5201): 35-37. 10.1038/223035a0PubMed

113.

Collier HO: A pharmacological analysis of aspirin. Adv Pharmacol Chemother. 1969, 7: 333-405.PubMed

114.

Thoms HC, Dunlop MG, Stark LA: p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res. 2007, 67 (4): 1660-1669. 10.1158/0008-5472.CAN-06-1038PubMed

115.

Baliga BS, Pronczuk AW, Munro HN: Mechanism of cycloheximide inhibition of protein synthesis in a cell-free system prepared from rat liver. J Biol Chem. 1969, 244 (16): 4480-4489.PubMed

116.

Obrig TG, Culp WJ, McKeehan WL, Hardesty B: The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J Biol Chem. 1971, 246 (1): 174-181.PubMed

117.

Kota BP, Huang TH, Roufogalis BD: An overview on biological mechanisms of PPARs. Pharmacol Res. 2005, 51 (2): 85-94. 10.1016/j.phrs.2004.07.012PubMed

118.

Qi C, Zhu Y, Reddy JK: Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem Biophys. 2000, 32 Spring: 187-204. 10.1385/CBB:32:1-3:187PubMed

119.

Wang T, Xu J, Yu X, Yang R, Han ZC: Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol. 2006, 58 (1): 1-14.PubMed

120.

Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S: Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res. 2003, 63 (5): 958-964.PubMed

121.

Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M, Lisanti MP, Chatterjee VK, Lazar MA, Pestell RG: Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol. 2001, 21 (9): 3057-3070. 10.1128/MCB.21.9.3057-3070.2001PubMedCentralPubMed

122.

Gingras AC, Raught B, Sonenberg N: mTOR signaling to translation. Curr Top Microbiol Immunol. 2004, 279: 169-197.PubMed

123.

Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 2004, 18 (16): 1926-1945. 10.1101/gad.1212704PubMed

124.

Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N: mTOR, translation initiation and cancer. Oncogene. 2006, 25 (48): 6416-6422. 10.1038/sj.onc.1209888PubMed

125.

Mita MM, Mita A, Rowinsky EK: Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer. 2003, 4 (2): 126-137.PubMed

126.

Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N: mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006, 94 (2): 195-199. 10.1038/sj.bjc.6602902PubMedCentralPubMed

127.

Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL: A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994, 369 (6483): 756-758. 10.1038/369756a0PubMed

128.

Chiu MI, Katz H, Berlin V: RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A. 1994, 91 (26): 12574-12578. 10.1073/pnas.91.26.12574PubMedCentralPubMed

129.

Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH: RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994, 78 (1): 35-43. 10.1016/0092-8674(94)90570-3PubMed

130.

Wiederrecht GJ, Sabers CJ, Brunn GJ, Martin MM, Dumont FJ, Abraham RT: Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells. Prog Cell Cycle Res. 1995, 1: 53-71.PubMed

131.

Datta SR, Brunet A, Greenberg ME: Cellular survival: a play in three Akts. Genes Dev. 1999, 13 (22): 2905-2927. 10.1101/gad.13.22.2905PubMed

132.

Shaw RJ, Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006, 441 (7092): 424-430. 10.1038/nature04869PubMed

133.

Woodgett JR: Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol. 2005, 17 (2): 150-157. 10.1016/j.ceb.2005.02.010PubMed

134.

Janus A, Robak T, Smolewski P: The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett. 2005, 10 (3): 479-498.PubMed

135.

Carraway H, Hidalgo M: New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res. 2004, 6 (5): 219-224. 10.1186/bcr927PubMedCentralPubMed

136.

Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC, Meric-Bernstam F: Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res. 2005, 65 (5): 1961-1972. 10.1158/0008-5472.CAN-04-2501PubMed

137.

Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S: Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem. 1998, 273 (23): 14424-14429. 10.1074/jbc.273.23.14424PubMed

138.

Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 2004, 10 (20): 7031-7042. 10.1158/1078-0432.CCR-04-0361PubMed

139.

Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res. 2004, 10 (3): 1013-1023. 10.1158/1078-0432.CCR-03-0043PubMed

140.

Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002, 1 (4): 287-299. 10.1038/nrd772PubMed

141.

Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001, 7 (4): 971-976.PubMed

142.

Vigushin DM, Coombes RC: Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002, 13 (1): 1-13. 10.1097/00001813-200201000-00001PubMed

143.

Dokmanovic M, Marks PA: Prospects: histone deacetylase inhibitors. J Cell Biochem. 2005, 96 (2): 293-304. 10.1002/jcb.20532PubMed

144.

Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?. Cancer Cell. 2003, 4 (1): 13-18. 10.1016/S1535-6108(03)00165-XPubMed

145.

Marks PA, Jiang X: Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle. 2005, 4 (4): 549-551.PubMed

146.

Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006, 6 (1): 38-51. 10.1038/nrc1779PubMed

147.

Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, Tofilon PJ: Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 2004, 64 (1): 316-321. 10.1158/0008-5472.CAN-03-2630PubMed

148.

Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ: Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer. 2005, 114 (3): 380-386. 10.1002/ijc.20774PubMed

149.

Camphausen K, Scott T, Sproull M, Tofilon PJ: Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res. 2004, 10 (18 Pt 1): 6066-6071. 10.1158/1078-0432.CCR-04-0537PubMed

150.

Kim IA, Shin JH, Kim IH, Kim JH, Kim JS, Wu HG, Chie EK, Ha SW, Park CI, Kao GD: Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res. 2006, 12 (3 Pt 1): 940-949. 10.1158/1078-0432.CCR-05-1230PubMed

151.

Kim JH, Shin JH, Kim IH: Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys. 2004, 59 (4): 1174-1180. 10.1016/j.ijrobp.2004.03.001PubMed

152.

Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63 (21): 7291-7300.PubMed

153.

Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002, 2 (2): 101-112. 10.1038/nrc721PubMed

154.

Caldon CE, Daly RJ, Sutherland RL, Musgrove EA: Cell cycle control in breast cancer cells. J Cell Biochem. 2006, 97 (2): 261-274. 10.1002/jcb.20690PubMed

155.

Cotelle V, Meek SE, Provan F, Milne FC, Morrice N, MacKintosh C: 14-3-3s regulate global cleavage of their diverse binding partners in sugar-starved Arabidopsis cells. Embo J. 2000, 19 (12): 2869-2876. 10.1093/emboj/19.12.2869PubMedCentralPubMed

156.

Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001, 8 (8): 739-758. 10.1016/S1074-5521(01)00056-4PubMed

157.

Lee DH, Goldberg AL: Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 1998, 8 (10): 397-403. 10.1016/S0962-8924(98)01346-4PubMed

158.

Ganiatsas S, Dow R, Thompson A, Schulman B, Germain D: A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT. Oncogene. 2001, 20 (28): 3641-3650. 10.1038/sj.onc.1204501PubMed

159.

LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional actvities for the p21 family of CDK inhibitors. Genes and Development. 1997, 11 (12): 847-862.PubMed

160.

Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ: The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. Embo J. 1999, 18 (6): 1571-1583. 10.1093/emboj/18.6.1571PubMedCentralPubMed

161.

Diehl JA, Sherr CJ: A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol. 1997, 17 (12): 7362-7374.PubMedCentralPubMed

Title: The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention
Author: John P Alao
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2007
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-6-24

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses

Nasopharyngeal carcinoma: molecular biomarker discovery and progress

O 6 -methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies

Contribution of oncoproteomics to cancer biomarker discovery

DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets

Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model

Keynote webinar | Spotlight on antibody–drug conjugates in cancer